{"id":651907,"date":"2023-05-17T20:04:01","date_gmt":"2023-05-17T20:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=651907"},"modified":"2023-05-17T20:04:01","modified_gmt":"2023-05-17T20:04:01","slug":"exophthalmos-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-key-companies-horizon-pharma-sling-therapeutics-novartis-pharmaceuticals-immunovant-sci","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/exophthalmos-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-key-companies-horizon-pharma-sling-therapeutics-novartis-pharmaceuticals-immunovant-sci_651907.html","title":{"rendered":"Exophthalmos Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies &#8211; Horizon Pharma, Sling Therapeutics, Novartis Pharmaceuticals, Immunovant Sci"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Exophthalmos Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies - Horizon Pharma, Sling Therapeutics, Novartis Pharmaceuticals, Immunovant Sci\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Exophthalmos Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies - Horizon Pharma, Sling Therapeutics, Novartis Pharmaceuticals, Immunovant Sci\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Exophthalmos- Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Exophthalmos, historical and forecasted epidemiology as well as the Exophthalmos market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s <strong>&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/exophthalmos-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Exophthalmos- Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>&#8221; report delivers an in-depth understanding of the Exophthalmos, historical and forecasted epidemiology as well as the Exophthalmos market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Exophthalmos Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Exophthalmos (also known as proptosis) is the protrusion of one eye or both anteriorly out of the orbit. It derives from Greek, meaning &#8216;bulging eyes. It occurs due to an increase in orbital contents in the regular anatomy of the bony orbit. Depending on the underlying cause, exophthalmos may be accompanied by systemic symptoms. Vision may be disturbed if the optic nerve is compressed in conjunction with the underlying etiology of exophthalmos.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/b6e6c94daf1f8b47889d86128cc58402.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Exophthalmos Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bartley et al had reported a frequency of 2.9 cases per 100,000 population per year in men and 16 cases per 100,000 population per year in women. They also observed a bimodal distribution in both sexes, with women showing one peak at age 40-44 years and the other peak at age 60-64 years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The exact prevalence (i.e. the number of people who have a disorder in a specific population at a specific time) of thyroid eye disease is not known but is estimated to be 16 per 100,000 women in the general population, and 2.9 per 100,000 men in the general population<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/exophthalmos-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Exophthalmos Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Exophthalmos&nbsp; Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total&nbsp; Exophthalmos incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total&nbsp; Exophthalmos prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total&nbsp; Exophthalmos treatment cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total&nbsp; Exophthalmos diagnostic cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Exophthalmos Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Exophthalmos market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Exophthalmos market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This segment gives a thorough detail of Exophthalmos market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria&#8217;s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.According to DelveInsight, the Exophthalmos market in 7MM is expected to change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Key Companies Working in the Exophthalmos Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Horizon Pharma&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sling Therapeutics&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunovant Sciences Gmbh&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Exophthalmos Therapies Covered and Analyzed in the Report:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">LIPO-102<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Teprotumumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Linsitinib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tepezza<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/exophthalmos-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Key Companies and Emerging Therapies in the Exophthalmos Market.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Exophthalmos&nbsp; Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of&nbsp; Exophthalmos&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Exophthalmos &nbsp; Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Exophthalmos &nbsp; Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/exophthalmos-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Exophthalmos Market Outlook.<\/a> <br \/><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=exophthalmos-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-key-companies-horizon-pharma-sling-therapeutics-novartis-pharmaceuticals-immunovant-sci\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=exophthalmos-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-key-companies-horizon-pharma-sling-therapeutics-novartis-pharmaceuticals-immunovant-sci\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Exophthalmos- Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Exophthalmos, historical and forecasted epidemiology as well as the Exophthalmos market trends in the United States, EU5 (Germany, Spain, Italy, France, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/exophthalmos-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-key-companies-horizon-pharma-sling-therapeutics-novartis-pharmaceuticals-immunovant-sci_651907.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-651907","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/651907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=651907"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/651907\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=651907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=651907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=651907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}